News Chart MoonLake Immunotherapeutics

Equities

MLTX

KY61559X1045

Market Closed - Nasdaq Other stock markets 21:00:00 18/06/2024 BST			5-day change	1st Jan Change
39.49 ^USD	-1.69%		-9.05%	-34.61%

06-10	MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from Both FDA and EMA on Path for the Phase 3 Program for the Nanobody Sonelokimab in Psoriatic Arthritis	CI
05-07	MoonLake Immunotherapeutics Q1 Net Loss Widens	MT

633358efc0423451767987.VYgXIrLH8nxN6lFH1grKUSDXo-xap-QvTgd-dF4dpe4.McNaT8u0uU1_3wMw7k24PEuG5a4u5I8Cd04uHShl-r0f_VAQ4JLBFzuLOg~c2290eddc6d2fd912c9ac98af022954d